KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Change in Accured Expenses (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Change in Accured Expenses data on record, last reported at $203000.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 99.08% year-over-year to $203000.0; the TTM value through Dec 2025 reached -$1.2 million, up 74.13%, while the annual FY2025 figure was -$1.2 million, 74.13% up from the prior year.
  • Change in Accured Expenses reached $203000.0 in Q4 2025 per PACB's latest filing, down from $1.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $22.1 million in Q4 2024 and bottomed at -$18.1 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is -$390500.0, with a median of -$874000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: plummeted 648.06% in 2021, then skyrocketed 5497.21% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.2 million in 2021, then tumbled by 188.96% to -$2.0 million in 2022, then soared by 120.19% to $394000.0 in 2023, then surged by 5497.21% to $22.1 million in 2024, then crashed by 99.08% to $203000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $203000.0 in Q4 2025, $1.0 million in Q3 2025, and -$2.7 million in Q2 2025.